Asymptomatic transmission and high community burden of seasonal influenza in an urban and a rural community in South Africa, 2017-18 (PHIRST): a population cohort study.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
06 2021
Historique:
received: 07 10 2020
revised: 23 02 2021
accepted: 26 02 2021
pubmed: 22 5 2021
medline: 17 7 2021
entrez: 21 5 2021
Statut: ppublish

Résumé

Data on influenza community burden and transmission are important to plan interventions especially in resource-limited settings. However, data are limited, particularly from low-income and middle-income countries. We aimed to evaluate the community burden and transmission of influenza in a rural and an urban setting in South Africa. In this prospective cohort study approximately 50 households were selected sequentially from both a rural setting (Agincourt, Mpumalanga Province, South Africa; with a health and sociodemographic surveillance system) and an urban setting (Klerksdorp, Northwest Province, South Africa; using global positioning system data), enrolled, and followed up for 10 months in 2017 and 2018. Different households were enrolled in each year. Households of more than two individuals in which 80% or more of the occupants agreed to participate were included in the study. Nasopharyngeal swabs were collected twice per week from participating household members irrespective of symptoms and tested for influenza using real-time RT-PCR. The primary outcome was the incidence of influenza infection, defined as the number of real-time RT-PCR-positive episodes divided by the person-time under observation. Household cumulative infection risk (HCIR) was defined as the number of subsequent infections within a household following influenza introduction. 81 430 nasopharyngeal samples were collected from 1116 participants in 225 households (follow-up rate 88%). 917 (1%) tested positive for influenza; 178 (79%) of 225 households had one or more influenza-positive individual. The incidence of influenza infection was 43·6 (95% CI 39·8-47·7) per 100 person-seasons. 69 (17%) of 408 individuals who had one influenza infection had a repeat influenza infection during the same season. The incidence (67·4 per 100 person-seasons) and proportion with repeat infections (22 [23%] of 97 children) were highest in children younger than 5 years and decreased with increasing age (p<0·0001). Overall, 268 (56%) of 478 infections were symptomatic and 66 (14%) of 478 infections were medically attended. The overall HCIR was 10% (109 of 1088 exposed household members infected [95% CI 9-13%). Transmission (HCIR) from index cases was highest in participants aged 1-4 years (16%; 40 of 252 exposed household members) and individuals with two or more symptoms (17%; 68 of 396 exposed household members). Individuals with asymptomatic influenza transmitted infection to 29 (6%) of 509 household contacts. HIV infection, affecting 167 (16%) of 1075 individuals, was not associated with increased incidence or HCIR. Approximately half of influenza infections were symptomatic, with asymptomatic individuals transmitting influenza to 6% of household contacts. This suggests that strategies, such as quarantine and isolation, might be ineffective to control influenza. Vaccination of children, with the aim of reducing influenza transmission might be effective in African settings given the young population and high influenza burden. US Centers for Disease Control and Prevention.

Sections du résumé

BACKGROUND
Data on influenza community burden and transmission are important to plan interventions especially in resource-limited settings. However, data are limited, particularly from low-income and middle-income countries. We aimed to evaluate the community burden and transmission of influenza in a rural and an urban setting in South Africa.
METHODS
In this prospective cohort study approximately 50 households were selected sequentially from both a rural setting (Agincourt, Mpumalanga Province, South Africa; with a health and sociodemographic surveillance system) and an urban setting (Klerksdorp, Northwest Province, South Africa; using global positioning system data), enrolled, and followed up for 10 months in 2017 and 2018. Different households were enrolled in each year. Households of more than two individuals in which 80% or more of the occupants agreed to participate were included in the study. Nasopharyngeal swabs were collected twice per week from participating household members irrespective of symptoms and tested for influenza using real-time RT-PCR. The primary outcome was the incidence of influenza infection, defined as the number of real-time RT-PCR-positive episodes divided by the person-time under observation. Household cumulative infection risk (HCIR) was defined as the number of subsequent infections within a household following influenza introduction.
FINDINGS
81 430 nasopharyngeal samples were collected from 1116 participants in 225 households (follow-up rate 88%). 917 (1%) tested positive for influenza; 178 (79%) of 225 households had one or more influenza-positive individual. The incidence of influenza infection was 43·6 (95% CI 39·8-47·7) per 100 person-seasons. 69 (17%) of 408 individuals who had one influenza infection had a repeat influenza infection during the same season. The incidence (67·4 per 100 person-seasons) and proportion with repeat infections (22 [23%] of 97 children) were highest in children younger than 5 years and decreased with increasing age (p<0·0001). Overall, 268 (56%) of 478 infections were symptomatic and 66 (14%) of 478 infections were medically attended. The overall HCIR was 10% (109 of 1088 exposed household members infected [95% CI 9-13%). Transmission (HCIR) from index cases was highest in participants aged 1-4 years (16%; 40 of 252 exposed household members) and individuals with two or more symptoms (17%; 68 of 396 exposed household members). Individuals with asymptomatic influenza transmitted infection to 29 (6%) of 509 household contacts. HIV infection, affecting 167 (16%) of 1075 individuals, was not associated with increased incidence or HCIR.
INTERPRETATION
Approximately half of influenza infections were symptomatic, with asymptomatic individuals transmitting influenza to 6% of household contacts. This suggests that strategies, such as quarantine and isolation, might be ineffective to control influenza. Vaccination of children, with the aim of reducing influenza transmission might be effective in African settings given the young population and high influenza burden.
FUNDING
US Centers for Disease Control and Prevention.

Identifiants

pubmed: 34019838
pii: S2214-109X(21)00141-8
doi: 10.1016/S2214-109X(21)00141-8
pmc: PMC8262603
mid: NIHMS1710464
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e863-e874

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Organisme : NCIRD CDC HHS
ID : U51 IP000155
Pays : United States

Investigateurs

Amelia Buys (A)
Angie Mathee (A)
Anne von Gottberg (A)
Brigitte Language (B)
Cheryl Cohen (C)
Lorens Maake (L)
Floidy Wafawanaka (F)
Florette Treurnicht (F)
Jackie Kleynhans (J)
Jocelyn Moyes (J)
Kathleen Kahn (K)
Katlego Mothlaoleng (K)
Limakatso Lebina (L)
Maimuna Carrim (M)
Meredith L McMorrow (ML)
Neil A Martinson (NA)
Nicole Wolter (N)
Orienka Hellferscee (O)
Ryan G Wagner (RG)
Stefano Tempia (S)
Stuart Piketh (S)
Thulisa Mkhencele (T)
F Xavier Gómes-Olivé (FX)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests CC reports grants from Sanofi Pasteur, Advanced Vaccine Initiative, US Centers for Disease Control and Prevention, and the Billl & Melinda Gates Foundation; and travel fees from Parexel. AvG and NW report grants from Sanofi Pasteur and the Billl & Melinda Gates Foundation. NAM reports grants from Pfizer.

Références

J Infect Dis. 2019 Apr 19;219(10):1605-1615
pubmed: 30541140
N Engl J Med. 2010 Jun 10;362(23):2175-2184
pubmed: 20558368
J Infect Dis. 2011 May 1;203(9):1309-15
pubmed: 21378375
Am J Hyg. 1953 Jul;58(1):16-30
pubmed: 13065268
Influenza Other Respir Viruses. 2017 May;11(3):254-262
pubmed: 28207989
Clin Infect Dis. 2019 Aug 30;69(6):1036-1048
pubmed: 30508065
Clin Infect Dis. 2018 May 2;66(10):1511-1518
pubmed: 29206909
Influenza Other Respir Viruses. 2018 Jan;12(1):171-182
pubmed: 28991409
Vaccine. 2019 Jan 3;37(1):25-33
pubmed: 30471956
Emerg Infect Dis. 2018 Oct;24(10):1882-1888
pubmed: 30226161
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Influenza Other Respir Viruses. 2019 Mar;13(2):123-132
pubmed: 29989680
Emerg Infect Dis. 2016 Jun;22(6):1052-6
pubmed: 27191967
Epidemiology. 2015 Nov;26(6):862-72
pubmed: 26133025
Epidemiol Infect. 1993 Feb;110(1):145-60
pubmed: 8432318
Am J Epidemiol. 2012 May 15;175(10):1062-74
pubmed: 22411862
J Infect Dis. 2019 Jan 9;219(3):347-357
pubmed: 30016464
Clin Infect Dis. 2017 Oct 16;65(9):1532-1541
pubmed: 29020267
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Emerg Infect Dis. 2020 May;26(5):967-975
pubmed: 32027586
Clin Infect Dis. 2017 Mar 15;64(6):736-742
pubmed: 28011603
Influenza Other Respir Viruses. 2019 Sep;13(5):484-495
pubmed: 31187609
Am J Epidemiol. 1985 Jun;121(6):811-22
pubmed: 4014174
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
Glob Health Action. 2016 Oct 24;9:32795
pubmed: 27782873
Am J Hyg. 1958 Sep;68(2):190-212
pubmed: 13571232
J Infect Dis. 2018 Sep 8;218(8):1228-1237
pubmed: 29800425
Int J Epidemiol. 2012 Aug;41(4):988-1001
pubmed: 22933647
Lancet Respir Med. 2014 Jun;2(6):445-54
pubmed: 24717637
PLoS One. 2015 Jun 11;10(6):e0125200
pubmed: 26066651
Euro Surveill. 2015;20(39):
pubmed: 26537222

Auteurs

Cheryl Cohen (C)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: cherylc@nicd.ac.za.

Jackie Kleynhans (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Jocelyn Moyes (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.

Meredith L McMorrow (ML)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

Florette K Treurnicht (FK)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Orienka Hellferscee (O)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Azwifarwi Mathunjwa (A)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Anne von Gottberg (A)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Nicole Wolter (N)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, University of the Witwatersrand, Johannesburg, South Africa.

Neil A Martinson (NA)

Perinatal HIV Research Unit, South African Medical Research Council, Soweto Matlosana Collaborating Centre for HIV/AIDS and Tuberculosis, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundations, Centre of Excellence for Biomedical Tuberculosis Research, University of the Witwatersrand, Johannesburg, South Africa; Center for Tuberculosis Research, Johns Hopkins University, Baltimore, MD, USA.

Kathleen Kahn (K)

South African Medical Research Council Rural Public Health and Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa.

Limakatso Lebina (L)

Perinatal HIV Research Unit, South African Medical Research Council, Soweto Matlosana Collaborating Centre for HIV/AIDS and Tuberculosis, University of the Witwatersrand, Johannesburg, South Africa.

Katlego Mothlaoleng (K)

Perinatal HIV Research Unit, South African Medical Research Council, Soweto Matlosana Collaborating Centre for HIV/AIDS and Tuberculosis, University of the Witwatersrand, Johannesburg, South Africa.

Floidy Wafawanaka (F)

South African Medical Research Council Rural Public Health and Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa.

Francesc Xavier Gómez-Olivé (FX)

South African Medical Research Council Rural Public Health and Health Transitions Research Unit (Agincourt), University of the Witwatersrand, Johannesburg, South Africa.

Thulisa Mkhencele (T)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.

Angela Mathee (A)

Environment and Health Research Unit, South African Medical Research Council, Johannesburg, South Africa.

Stuart Piketh (S)

Unit for Environmental Science and Management, Climatology Research Group, North-West University, Potchefstroom, South Africa.

Brigitte Language (B)

Unit for Environmental Science and Management, Climatology Research Group, North-West University, Potchefstroom, South Africa.

Stefano Tempia (S)

School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa; MassGenics, Duluth, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH